Anhidrotic Area and Safety of MEDITOXIN in Healthy Male Valunteers
NCT ID: NCT03647982
Last Updated: 2019-03-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
13 participants
INTERVENTIONAL
2018-03-20
2018-11-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacodynamic and Safety of MEDITOXIN® in Healthy Male Volunteers
NCT03317717
Treatment of MEDITOXIN® in Female Patients With Idiopathic Overactive Bladder
NCT03371342
Hyperhydrosis Treatment Using Botulinum Toxin
NCT03816046
Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis
NCT02565732
GSK1358820 (Botulinum Toxin A) PhIII DB & OL Study in Patients With Axillary Hyperhidrosis
NCT01128738
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
botulinum toxin 1U
Meditoxin
injection of MEDITOXIN into the intradermal of each contralateral upper back in equal doses
Botox
injection of Botox into the intradermal of each contralateral upper back in equal doses
botulinum toxin 3U(25U/1ml)
Meditoxin
injection of MEDITOXIN into the intradermal of each contralateral upper back in equal doses
Botox
injection of Botox into the intradermal of each contralateral upper back in equal doses
botulinum toxin 5U
Meditoxin
injection of MEDITOXIN into the intradermal of each contralateral upper back in equal doses
Botox
injection of Botox into the intradermal of each contralateral upper back in equal doses
botulinum toxin 10U
Meditoxin
injection of MEDITOXIN into the intradermal of each contralateral upper back in equal doses
Botox
injection of Botox into the intradermal of each contralateral upper back in equal doses
botulinum toxin 3U(50U/1ml)
Meditoxin
injection of MEDITOXIN into the intradermal of each contralateral upper back in equal doses
Botox
injection of Botox into the intradermal of each contralateral upper back in equal doses
botulinum toxin 3U(12.5U/1ml)
Meditoxin
injection of MEDITOXIN into the intradermal of each contralateral upper back in equal doses
Botox
injection of Botox into the intradermal of each contralateral upper back in equal doses
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Meditoxin
injection of MEDITOXIN into the intradermal of each contralateral upper back in equal doses
Botox
injection of Botox into the intradermal of each contralateral upper back in equal doses
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
20 Years
45 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medy-Tox
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Catholic University St. Paul Hospital
Seoul, Dongdaemun-gu, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MT01-KR17PAH110
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.